GeoWealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GeoWealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$539K	Buy	1,207 +197	+20%	+$91.9K	0.02%	459
2025 Q4	$458K	Sell	1,010 -8	-0.8%	-$3.45K	0.02%	465
2025 Q3	$399K	Buy	1,018 +64	+7%	+$26.7K	0.01%	497
2025 Q2	$425K	Sell	954 -89	-9%	-$41K	0.02%	441
2025 Q1	$506K	Sell	1,043 -270	-21%	-$126K	0.02%	418
2024 Q4	$529K	Sell	1,313 -1,292	-50%	-$599K	0.02%	455
2024 Q3	$1.21M	Buy	2,605 +1,346	+107%	+$647K	0.04%	266
2024 Q2	$590K	Buy	1,259 +212	+20%	+$92K	0.03%	389
2024 Q1	$438K	Buy	+1,047	New	+$443K	0.02%	477

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GeoWealth Management's VRTX Position: Q1 2026 in Review

GeoWealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, buying an estimated $91.9K and bringing the position to 1,207 shares worth $539K. The position accounts for 0.02% of the portfolio, ranked #459.

GeoWealth Management first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.21M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

GeoWealth Management held 1,207 shares of Vertex Pharmaceuticals worth $539K as of Q1 2026.
GeoWealth Management bought 197 Vertex Pharmaceuticals shares in Q1 2026, an estimated $91.9K.
Vertex Pharmaceuticals made up 0.02% of GeoWealth Management's portfolio in Q1 2026, its #459 holding.
GeoWealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
GeoWealth Management's Vertex Pharmaceuticals position peaked at $1.21M in Q3 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GeoWealth Management's 13F filing for Q1 2026, filed 13 May 2026.